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Abstract
High levels of plasminogen activator inhibitor (PAI-1) in tumors are associated with poor prognosis in several can-
cer types, and the reason for this association is not fully understood. Plasminogen activator inhibitor 1 has been
suggested to contribute to tumor growth by protecting cancer cells from apoptosis, and we have previously shown
that wild type murine fibrosarcoma cells are significantly more resistant to apoptosis induced by chemotherapy
than PAI-1–deficient fibrosarcoma cells. Here, we further investigated the molecular mechanisms underlying the
antiapoptotic function of PAI-1 focusing on the phosphatidylinositol 3-phosphate kinase (PI3K)/Akt cell survival path-
way. We demonstrate that the activation level of the Akt cell survival pathway is reduced in PAI-1–deficient cells.
Inhibition of either PI3K or Akt by synthetic inhibitors sensitized the wild type but not the PAI-1–deficient cells to
etoposide-induced cell death. More importantly, reintroduction of PAI-1 expression in PAI-1–deficient cells induced
an increase in Akt activity and protection against etoposide-induced apoptosis. Concordantly, silencing of PAI-1 by
RNA interference in wild type fibrosarcoma cells decreased the level of active Akt, and this was accompanied by a
sensitization of the cells to etoposide-induced cell death. Altogether, our data suggest that PAI-1 influences sen-
sitivity to etoposide-induced apoptosis through the PI3K/Akt cell survival pathway by acting upstream of PI3K and
Akt. This points to PAI-1 as a possible therapeutic target in cancer diseases where PAI-1 inhibits chemotherapy-
induced apoptosis.
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Introduction
The plasminogen activator system plays an important role in tumor
growth and metastasis [1]. Urokinase-type plasminogen activator
(uPA) is an activator of plasminogen and has been reported to have
several tumor-promoting effects [2–4]. A large number of clinical
studies have shown a strong association between high tumor tissue
levels of uPA and poor cancer patient survival, supporting a major
role of uPA in cancer progression. The plasminogen activator system
is regulated by endogenous inhibitors, the serpin (serine protease in-
hibitor) gene family. One of these, plasminogen activator inhibitor 1
(PAI-1), is a secreted protein and is a major inhibitor of uPA [1]. On
the basis of the many preclinical and clinical studies that link uPA to
tumor progression, high PAI-1 levels in a tumor would be expected
to inhibit cancer progression in patients and thus relate to a more
favorable prognosis. However, a very large number of clinical studies
have demonstrated that high PAI-1 levels in tumors are associated
with poor prognosis in cancer [5–8]. The results have now reach a
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level of evidence that have prompted the American Association for
Clinical Oncology (ASCO) to recommend uPA and PAI-1 as prog-
nostic variables in patients with breast cancer [9].
Several mechanisms have been proposed to explain this apparent
discrepancy between what might be expected from high levels of
PAI-1 and the observed clinical correlations. Plasminogen activator
inhibitor 1 has been shown to stimulate angiogenesis [10–12], to
mediate/stimulate cell migration [13,14], and to modulate cell adhe-
sion [15]. It has also been suggested that PAI-1 modulates cell sig-
naling, and when it is bound to uPA, it can promote growth of
MCF-7 breast cancer cells through a sustained phosphorylation of
the extracellular signal–regulated kinases 1/2 (Erk1/2) [16]. Further-
more, PAI-1 has been suggested to inhibit apoptosis in vascular
smooth muscle cells through direct interaction with caspase-3 [17].
Finally, incubation of cancer cell lines with recombinant PAI-1 has
been demonstrated to inhibit apoptosis induced by cytotoxic drugs
[18]. It is still not known how PAI-1 mediates an antiapoptotic signal
from the extracellular space into the cell and which signaling path-
ways might be involved.
One pathway involved in a variety of cellular responses, including
the transmission of antiapoptotic survival signals leading to drug
resistance, is the phosphatidylinositol 3-kinase (PI3K)/Akt cell sig-
naling pathway [19,20]. The three Akt family members identified
in mammals — Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBδ [21] —
are activated by various stimuli in a PI3K-dependent manner [22,23]
and depend on phosphorylation of Thr308 and Ser473 [24]. Acti-
vated Akt phosphorylates a number of target proteins involved in
various cellular functions. For instance, the proapoptotic protein
Bad is phosphorylated to promote cell survival and phosphorylation
of Raf1 leads to inhibition of the Raf-MEK-ERK signaling pathway
[25]. Furthermore, Akt phosphorylates and inactivates glycogen
synthase kinase-3β (GSK-3β), leading to inhibition of glycogen syn-
thesis [26]. The tumor-suppressor phosphatase and tensin homolog
(PTEN), which is deleted or inactivated in many tumors, antagonizes
the PI3K/Akt cell signaling pathway [27]. Loss of PTEN expression
is known to cause Akt hyperactivation, leading to protection from
various apoptotic stimuli [28,29]. It has recently been demonstrated
that PAI-1 can regulate Akt activity that may involve inactivation of
PTEN [30]. We have previously shown that malignantly transformed
PAI-1–deficient cells are significantly more sensitive to apoptosis in-
duced by cytotoxic drugs than are wild type cells [31].
The aim of the present study was to investigate whether the PI3K/
Akt signaling pathway is involved in PAI-1–mediated inhibition of
drug-induced programmed cell death in murine fibrosarcoma cells.
The study describes the effect of selective inhibition of either PI3K
or Akt on chemotherapy-induced apoptosis in PAI-1 expressing wild
type and PAI-1–deficient murine fibrosarcoma cells. In addition, we
describe the effect of specific silencing of PAI-1 in wild type cells on
Akt activation and chemotherapy-induced apoptosis.
Materials and Methods
Cell Culture
Murine fibrosarcoma cells derived from either PAI-1–deficient
or wild type mice were generated as previously described [32]. In
brief, mice were bred heterozygous to heterozygous to obtain relevant
pairs of siblings representing gene-deficient and homozygous wild
type mice. Two pairs of fibrosarcoma cell lines were established,
and each pair of cell lines originated from mice born in the same
litter: Pko-I (PAI-1 gene-deficient), Pwt-I (wild type) and Pko-II
(PAI-1–deficient), Pwt-II (wild type). The cells were cultured in
M199/Hanks salts (GIBCO, Invitrogen A/S, Taastrup, Denmark)
supplemented with 10% fetal calf serum (complete medium, CM)
at 37°C and 5% CO2.
Compounds
Ly294002, Akt inh. VIII, and human insulin-like growth factor
(IGF-1) were from Calbiochem (San Diego, CA). Etoposide was from
Bristol-Myers Squibb (Lyngby, Denmark). Recombinant human PAI-1
and recombinant murine PAI-1 purified from Escherichia coli were
from American Diagnostica, Inc., Stamford, CT.
Regulation of Akt Activity
The cell lines were analyzed for the capacity to regulate the PI3K/
Akt signaling pathway by treating the cells with IGF-1 and etoposide.
Cells were seeded in 10-cm2 Petri dishes (4 × 105 cells per dish) and
grown for 24 hours before treatment. Cells were left untreated or
treated with 100 ng/ml IGF-1 for 15 minutes or 10 μM etoposide
for 4 and 24 hours. IGF-1–treated and –untreated cells were harvested,
and proteins were separated by SDS-PAGE and phosphor-Akt levels
were detected according to the immunoblot analysis protocol (see be-
low). Etoposide-treated and -untreated cells were harvested in cell lysis
buffer without phosphatase inhibitors, and Akt activity was measured
according to the Akt kinase assay kit (see below).
RNA Interference
Cells were seeded in 75-cm2 cell culture flask in CM without anti-
biotics. When cells were approximately 30% to 50% confluent, the
cells were transfected with Stealth RNAi (Invitrogen A/S) using X-
tremeGENE siRNA Transfection Reagent (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s instructions.
Two different RNAi constructs directed to PAI-1 mRNA were
used (PAI-1 RNAi), one attaching to the transcript at 375 in exon 2,
the other at 899 in exon 5. The targeted sequences were as follows:
UGACUUUGAAUCCCAUAGCAUCUUG (#2) and AAAGG-
GUGCAGCGAUGAACAUGCUG (#9).
As controls for the specificity of the PAI-1 silencing RNAi con-
structs, two corresponding mismatch constructs were used (Ctl RNAi):
UGAUCUCGUUUAACCCAUAACGUUG (#2C) and AAAGUG-
GUGGCGACGUAGACAACUG (#9C). Cells were treated for 4 to
144 hours with PAI-1 RNAi constructs at concentrations of 35 to
64 nM, as optimal for silencing of PAI-1 with minimal cytotoxicity.
Cytotoxicity Assay
For measurement of cytotoxicity, the lactate dehydrogenase (LDH)
release assay (Roche Applied Sciences, Mannheim, Germany) was
used. Cells were treated with PAI-1 RNAi or Ctl RNAi for 51 to
78 hours, then trypsinized and seeded in a 96-well plate (3500 cells
per well). After 24 hours, the cells were treated with indicated con-
centrations (Figures 2, C–D, and 5, A–B) of etoposide for 30 to
48 hours. LDH release was measured, and cytotoxicity was calculated
as previously described [31].
Apoptosis Assay
Apoptotic cell death can be measured by the presence of oligonu-
cleosomes in the cytoplasm. For this purpose, the Cell Death Detec-
tion ELISA Kit (Roche, Mannheim, Germany) was used. Cells were
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seeded in a 96-well plate (3500 cells/well). After 24 hours, cells were
treated with etoposide for another 48 hours, and the level of apopto-
sis was measured with the Cell Death Detection ELISA Kit accord-
ing to the manufacturer’s instructions.
Reintroduction of PAI-1 in Pko-1 Cells
Murine PAI-1 was a clone from the pcDNA-3.1-neo vector (gen-
erously provided by Ann Gils) to the pcDNA-3.1-hyg vector. Trans-
fections were performed using FuGENE 6 transfection reagent
(Roche, Mannheim, Germany). Pko-1 cells were seeded out in a
six-well plate with 1 × 105 cells/well in 2-ml medium. After 24 hours,
the medium was changed, and the cells were transfected with
pcDNA-3.1-PAI-1 and empty vector (transfection mix: 6:1 ratio of
FuGENE reagent (μl) to plasmid DNA (μg)). After 48 hours, me-
dium was changed to a medium containing 150 ng/ml hygromycin
(Sigma-Aldrich, Brøndby, Denmark). After 14 days, selection of
transfected cells was completed. To obtain single-cell clones with a
high expression of PAI-1, dilution cloning was performed. To avoid
clonal heterogeneity, four single-cell clones of Pko-1–transfected cells
expressing medium and high levels of PAI-1 were mixed in equal
ratio (Pko-PAI-1-pool) and four vector control–transfected single-
cell clones were mixed in an equal ratio (Pko-vector-pool) to obtain
pool population of PAI-1–expressing Pko-1 cells and vector control–
transfected Pko-1 cells.
Akt Kinase Assay
Akt kinase activity was measured by an Akt kinase assay kit (Cell
Signaling Technology, Inc., Danvers, MA). Briefly, cells were seeded
in 6-cm Petri dishes (4 × 105 per dish) and grown for 24 hours. Me-
dium was aspirated, and cells were washed twice in 500 μl of ice-
cold PBS. Cells were lysed for 5 minutes in 500 μl of cell lysis buffer
containing 1 mM Pefa-block. Then cells were scraped off, transferred
to an Eppendorf tube, and sonicated on ice. Twenty microliters of
immobilized anti–Akt antibody bead slurry was added to 400 μl of
cell lysate and incubated with gentle rocking overnight at 4°C. Cell
lysate/immobilized antibody was centrifuged at 14,000g for 30 sec-
onds at 4°C. Pellet was washed twice with 500 μl of ice-cold cell lysis
buffer and twice with 500 μl of ice-cold kinase buffer. The pellet
was suspended in 50 μl of 1× kinase buffer supplemented with
1 μl of 10 mM ATP and 1 μg of GSK-3 fusion protein. The mixture
was incubated for 30 minutes at 30°C. The reaction was terminated
with 25 μl 3× LSB + βME Buffer and boiled for 5 minutes. Phos-
phorylated GSK-3 fusion protein was detected by SDS-PAGE with
an anti–phospho-GSK-3 antibody (1:1000).
RNA Extraction and Reverse Transcription
Cells transfected with 50 nM of the two PAI-1 RNAi constructs,
Ctl RNAi constructs or transfection reagent alone, were grown in
Petri dishes at the indicated periods (Figure 3B). Cells were washed
with cold PBS and then harvested by scraping with a sterile cell
scraper and collected in Eppendorf tubes. The cells were washed
again with cold PBS and centrifuged at 300g for 5 minutes at 4°C.
The cell pellet was lysed in 175 μl of lysis buffer (SV Total RNA
Isolation System; Promega, Madison, WI) and stored at −80°C until
RNA extraction. When all samples were collected, RNA was ex-
tracted with a spin column kit (SV Total RNA Isolation System;
Promega) according to the manufacturer’s instructions. This proce-
dure includes an on-column DNase treatment, minimizing the risk
of DNA contamination. The concentration of total RNA was mea-
sured spectrophotometrically.
Two micrograms of total RNA were transcribed into cDNA using
the first-strand cDNA Synthesis Kit (Fermentas, Helsingborg, Swe-
den). The total volume of the reaction was 25 μl consisting of 1×
reaction buffer, 0.8 mM dNTPs, 20 U of RiboLock RNase inhibitor,
0.5 μg of oligo(dT) primer, 0.2 μg of random hexamer primer, and
40 U of M-MuLV reverse transcriptase. Samples were incubated at
25°C for 10 minutes, followed by 42°C for 1 hour. The reaction
was terminated by incubating at 95°C for 5 minutes followed by
cooling on ice.
Quantitative Polymerase Chain Reaction
All primer sets used were intron spanning to avoid false-positive
results from contaminating genomic DNA. All samples were mea-






Quantitative polymerase chain reaction (Q-PCR) was carried out
using SYBR Green I detection and the LightCycler 480 (Roche Di-
agnostics, Hvidovre, Denmark). Reactions were carried out in 96-
well plates with 2 μl of cDNA in 20-μl reaction volumes consisting
of 1× FastStart Master SYBR Green Mix and 0.5 μM of the gene-
specific primer. The amplification program was as follows: prein-
cubation for fast start polymerase activation at 95°C for 5 minutes,
followed by 45 amplification cycles [95°C for 10 seconds (20°C/sec),
60°C for 10 seconds (20°C/sec), and 72°C for 10 to 12 seconds
(20°C/sec)]. SYBR Green fluorescence was acquired at 72°C in each
amplification cycle. After the end of the last cycle, the melting curve
was generated by starting the fluorescence acquisition at 65°C and
taking measurements every 0.1 seconds until 95°C was reached.
Relative quantification was done using the Relative Quantification
software (LightCycler, Roche, Hvidovre, Denmark).
Immunoblot Analysis
Cells were seeded in 10-cm Petri dishes in CM. At 90% conflu-
ence, cells were washed with cold PBS, scraped off the culture dish
with a sterile cell scraper, and collected in Eppendorf tubes. The cell
pellet was resuspended in 50 μl of lysis buffer (0.5% Triton X-100,
25 mM HEPES, 1.5 mM MgCl2, 1 mM EGTA) supplemented with
protease inhibitors (10 μg/ml aprotenin, 1 μg/ml pepstatin a, 1 μg/ml
leupeptin, 1 μM Pefa-block) and phosphatase inhibitors (1 mM so-
dium fluoride, 1 mM sodium orthovanadate). All inhibitors were from
Sigma-Aldrich Denmark A/S.
Cells were left on ice for 30 minutes followed by centrifugation at
20.000 g for 5 minutes at 4°C. The protein concentration in each
sample was quantified by BCA Protein Assay Kit (Pierce, Rockford,
IL) Cell lysates were mixed with 0.25 volume 4× Laemmli sample
buffer containing 5% β-mercaptoethanol and boiled for 5 minutes.
Equal amounts of protein were separated by SDS–gel electrophoresis
using a 12% polyacrylamide gel and blotted on nitrocellulose paper.
The blot was blocked in PBS + 0.1% Tween 20 containing 5% dry
milk for 1 hour.
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The primary antibodies used were anti–phospho-Akt (Ser473), anti-
Akt, anti–phospho-Raf1 (Ser259), anti-Raf1, anti–phospho-GSK-3β
(Ser9), anti–GSK-3β, anti–phospho-PTEN (Ser380), anti-PTEN (all
diluted 1:1000; Cell Signaling Technology Inc.), anti–murine PAI-1
(3 μg/ml; American Diagnostica, Inc.), and GAPDH (1:80,000;
Biogenesis, UK). The blots were incubated with primary antibodies,
diluted in PBS, supplemented with 0.1 Tween 20 and 1% dry milk
(5% dry milk for anti–PAI-1 antibody) over night, then washed
3× in PBS supplemented with 0.1 Tween 20, and subsequently incu-
bated with respective HRP–conjugated secondary antibodies (1:2000
to 1:10,000; Dako, Glostrup, Denmark A/S) in PBS supplemented
with 0.1% Tween 20 and 1% dry milk. The blots were developed
by the ECL detection system (Amersham Bioscience, Little Chalfont,
UK) according to the manufacturer’s instructions. The band densities
were quantified by the UVP VisionWorksLS Image Acquisition and
Analysis Software.
Statistics
Student’s t test was used in the experiment where PAI-1 was rein-
troduced into the PAI-1–deficient cells to calculate if the reintroduc-
tion of PAI-1 induced a protection from cell death. In the experiment
where PAI-1 was silenced by RNAi, a one-sample t test was used to
calculate if fold induction in cytotoxicity had a distribution different
from 1. P values were considered significant when P < .05.
Results
Activation Level of PI3K/Akt Signaling Pathway Is Reduced in
PAI-1–Deficient Fibrosarcoma Cells
First, the activation status of the PI3K/Akt cell signaling pathway
in PAI-1–expressing and PAI-1–deficient fibrosarcoma cell lines were
analyzed (Figure 1). The wild type cell lines (Pwt-I and Pwt-II)
showed significantly higher levels of Akt phosphorylation than the
PAI-1–deficient cell lines (Pko-I and Pko-II). In addition, the two
downstream targets of Akt, Raf-1 and GSK-3β, presented a higher
degree of phosphorylation in wild type cells compared to levels in
PAI-1–deficient cells, indicating that PAI-1 can activate the PI3K/
Akt cell signaling pathway. Next, it was investigated if the expression
levels or phosphorylation levels of the PI3K/Akt antagonist PTEN
were different between PAI-1–deficient fibrosarcoma cells and wild
type cells. No differences in either expression levels or phosphoryla-
tion levels of PTEN were observed (Figure 1). To analyze if PAI-1
can activate the Akt signaling pathway, recombinant human stable
PAI-1 and recombinant murine PAI-1 (500 ng/ml, 24 hours) were
added to PAI-1–deficient and PAI-1 wild type cells; however, no in-
fluence Akt phosphorylation level was observed (data not shown).
This may be because the murine cells are not responsive to human
PAI-1 and most of the murine PAI-1 is converted to its latent for-
mation before it can exert its effects on the cells. To analyze if the cell
lines were responsive to external stimuli, wild type and PAI-1 gene–
deficient cells were stimulated with IGF-1 and etoposide. Incuba-
tion with IGF-1 for 15 minutes induced a significant induction in
Akt phosphorylation levels for both wild type and PAI-1–deficient
cells (Figure 2A). Incubation with etoposide for 4 hours, however,
resulted in a distinct reduction in Akt activity in Pko-I and Pwt-I
cells (Figure 2B) and Pko-II and Pwt-II cells (data not shown). After
24 hours of treatment, Akt activity increased compared to the 4 hours
of treatment in both Pko-1 and Pwt-I cells; however, the level of Akt
activity was still lower than that of the untreated cells. These data
demonstrate that the PI3K/Akt signaling pathways in both the wild
type and PAI-1–deficient cell lines are responsive to growth promoter
and growth inhibitor stimuli. Furthermore, a higher Akt activation
level was observed in the Pwt-I cells compared to the Pko-I cells
(Figure 2B), demonstrating that the level of phosphorylated Akt cor-
relates with the level of Akt activity.
Wild Type Fibrosarcoma Cells Can Be Sensitized to
Etoposide-Induced Cell Death by Inhibition of the
PI3K/Akt Cell Signaling Pathway
To further analyze the role of the PI3K/AKT cell signaling path-
way in PAI-1–mediated protection against apoptosis, the cells were
incubated with specific synthetic inhibitors of PI3K and Akt followed
by induction of cell death by etoposide. Incubation with the PI3K
inhibitor Ly294002 or the Akt inhibitor Akt inh. VIII induced a
dose-dependent inhibition of phosphorylated Akt in both wild type
and PAI-1–deficient cells (Figure 3, A and B). To investigate if the
observed inhibition of Akt phosphorylation levels affected the sen-
sitivity to cell death of wild type and PAI-1–deficient cells, both
Figure 1. Akt is hyperactivated in wild type fibrosarcoma cells.
One large preparation of cell lysates of each of Pko-I, Pwt-I, Pko-
II, and Pwt-II cells, respectively, were used to detect PAI-1 and
components of the Akt cell survival pathway. Proteins (50 μg) were
separated by SDS-PAGE, and the blots were probed with specific
antibodies as indicated. After detecting phosphorylated forms of
the proteins, the blots were stripped and reprobed with an anti-
body recognizing the total level of the protein. The anti-Akt and
anti–phospho-Akt (P-Akt) antibodies recognize all three Akt family
members. Band densities were calculated as the density of the
phosphorylated protein divided by the density of the total amount
of the protein. GAPDH served as a loading control. The asterisk
indicates a background band. The immunoblot analysis was re-
peated once with a new preparation of cell lysate, and identical
results were obtained.
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cell lines were pretreated with Ly294002 or Akt inh. VIII followed
by treatment with etoposide. Etoposide was chosen as death inducer
because etoposide is used to treat sarcomas in the clinic. Treatment of
wild type cells with etoposide together with Ly294002 or Akt inh.
VIII induced an increase in cell death compared with cells treated
with only etoposide (Figure 3C ), whereas no increase in cell death
was observed in PAI-1–deficient cells pretreated with the inhibitors
(Figure 3D). The lack of induction in cytotoxicity by the inhibition
of PI3K and Akt in the Pko-I cells may be because the Pko-1 cells are
highly sensitive to etoposide compared with wild type cells and,
therefore, inhibition of the PI3K-Akt pathway will not further en-
hance the sensitivity of the cells. It was verified by the Cell Death
Detection ELISA Kit (Roche) that the induction in cell death by pre-
treatment with PI3K and Akt inhibitors correlated with an increase
in apoptosis (data not shown). Altogether, these results indicate that
PAI-1 can protect wild type fibrosarcoma cells against apoptosis by
activating the PI3K/Akt signaling survival pathway. It was further
analyzed if treatment of wild type cells with Ly294002 or Akt inh.
VIII induced PAI-1 expression; however, no induction in PAI-1 ex-
pression was observed (data not shown).
Reintroduction of PAI-1 in PAI-1–Deficient Cells Induces
an Increased Akt Activation and Protection from
Etoposide-Induced Apoptosis
To further investigate the involvement of the PI3K/Akt signal-
ing pathway in PAI-1–mediated protection from etoposide-induced
Figure 2. The PI3K/Akt signaling pathway is responsive to growth
inducer and growth inhibitor in both wild type and PAI-1–deficient
cells. Pko-I, Pko-II, Pwt-I, and Pwt-II cells were treated with IGF-1
for 15 minutes (A), and Pko-I and Pwt-I cell were treated with eto-
poside for 0, 4, and 24 hours (B). Phosphorylated Akt (P-Akt) was
detected by immunoblot analysis with an antibody recognizing all
three Akt family members phosphorylated on residue 473. Akt ki-
nase activity was measured by incubating immunoprecipitated Akt
from cell lysates with ATP and a GSK-3 fusion protein. The reaction
was analyzed by immunoblot analysis, and phosphorylated GSK-3
fusion protein was detected by an anti–phospho-GSK-3 antibody.
Band density was calculated as the density of the phosphorylated
protein (B) or as the density of the phosphorylated protein divided
by the density of GAPDH (A). Band densities were normalized to
the band density of the first lane(s) in both blots. GAPDH serves as
a loading control. The experiments were repeated once with es-
sentially same results.
Figure 3. Inhibitors of the PI3K/Akt cell survival pathway sensitize
wild type cells to etoposide-induced cells death. Ctl. indicates con-
trol; Eto10, etoposide 10 μM; Ly10, 5, 1, Ly 294002 10, 5, 1 μM;
Akt. 5, 1, 0.2, Akt inhibitor VIII 5, 1, 0.2 μM. Pwt-I and Pko-I cells
were treated with the inhibitor of PI3K (Ly294002) or Akt (Akt in-
hibitor VIII) for 2 hours (A, B) followed by 48 hours treatment with
etoposide (C, D). Phosphorylated Akt (P-Akt) was detected by im-
munoblot analysis with an antibody recognizing all three Akt family
members phosphorylated on residue 473, and total Akt was de-
tected with a pan Akt antibody recognizing all three Akt family
members. GAPDH served as a loading control. The immunoblot
analysis was repeated once with identical result. Cell death was
measured as percent LDH release. The cell death data shown is
representative of four independent experiments showing the es-
sential same result. Furthermore, the experiment was repeated
with Pko-II and Pwt-II cells with essential the same result.
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apoptosis, we reintroduced PAI-1 into the PAI-1–deficient cells by
stable transfection. Four single-cell clones expressing PAI-1 were
pooled in equal ratio to make a pool population (Pko-PAI-1-pool),
and PAI-1 expression from this pool population was lower but close
to the expression level in wild type cells (Figure 4A). Interestingly, the
Pko-PAI-1-pool cells had a higher Akt activation level compared to a
pool population of four vector control single-cell clones (Pko-vector-
pool; Figure 4B). To analyze if the reintroduction of PAI-1 affected
the sensitivity of the cells to etoposide-induced cell death, etoposide-
induced cytotoxicity and apoptosis of Pko-PAI-1-pool and Pko-vector-
pool cells were measured (Figure 4, C and D). Pko-PAI-1-pool cells
were significantly less sensitive to etoposide-induced cytotoxicity
and apoptosis compared to Pko-vector-pool cells, indicating that
PAI-1 expression confers protection to the Pko-I cells. Altogether,
these data further indicate that PAI-1 can protect fibrosarcoma cells
from etoposide-induced apoptosis through activation of the PI3K/
Akt signaling pathway.
RNAi-Mediated Silencing of PAI-1 Leads to a Reduction in
Phosphorylated Akt
To establish a more direct link between PAI-1 expression and Akt
activation, we used RNAi to specifically down-regulate PAI-1 and
reassess the influence that PAI-1 has on the level of Akt phosphory-
lation. Transient transfection of wild type fibrosarcoma cells with
RNAi directed against PAI-1 induced a reduction in PAI-1 protein
levels, reaching its lowest levels between 48 and 95 hours after treat-
ment (Figure 5A). The initial, significant increase in PAI-1 mRNA
levels in both RNAi-treated cells and control-treated cells (Figure 5B)
was found to be caused by addition of fresh CM to all cells when
RNAi treatment was initiated. After RNAi treatment, PAI-1 mRNA
levels gradually decreased, and PAI-1 mRNA levels in cells treated
with PAI-1 RNAi showed a faster decrease and reached a lower level
compared with PAI-1 mRNA levels in cells treated with the mis-
matching control RNAi construct.When corresponding PAI-1–protein
levels were measured by immunoblot analysis, a perfect correlation
between mRNA and protein levels was observed (Figure 5, A and
B). Thus, treatment of wild type cells with RNAi directed against
PAI-1 induced a specific silencing of PAI-1 expression.
RNAi-mediated silencing of PAI-1 in wild type fibrosarcoma
cells resulted in a significant reduction of Akt phosphorylation level
(Figure 6). The level of Akt phosphorylation was lower in wild type
cells treated with PAI-1 RNAi construct compared with wild type
cells treated with the transfection agent alone and with wild type cells
treated with the mismatching control RNAi construct and corre-
sponded to the levels of PAI-1 protein (Figure 6).
RNAi-Mediated Silencing of PAI-1 Sensitizes Fibrosarcoma
Cells to Etoposide-Induced Cell Death
Next, we investigated if silencing of PAI-1 could sensitize the cells
to etoposide-induced programmed cells death. Wild type cells were
transfected with RNAi against PAI-1 or a mismatching control before
etoposide treatment. Transfection with the control RNAi construct
induced a minor sensitizing effect on etoposide-induced cell death,
whereas RNAi-mediated silencing of PAI-1 induced a pronounced
Figure 4. Reintroduction of PAI-1 in PAI-1–deficient cells induces
an increased Akt activation and protection from etoposide-induced
apoptosis. (A) PAI-1 expression levels in Pko-I, Pwt-I, Pko-II, Pwt-II,
Pko-vector-pool, and Pko-PAI-1-pool were determined by immuno-
blot analysis with an anti–murine PAI-1 antibody (American Diag-
nostica, Inc.). GAPDH serves as loading control. (B) Akt kinase
activity was measured by incubating immunoprecipitated Akt from
cell lysates with ATP and a GSK-3 fusion protein. The reaction an-
alyzed by immunoblot analysis and phosphorylated GSK-3 fusion
protein was detected by an anti–phospho-GSK-3 antibody. Band
densities were normalized to the band density of the first lane.
The experiment was repeated at least once with essentially same
result. (C, D) Pko-vector-pool and Pko-PAI-1 pool cells were grown
in 24 hours before 48 hours of incubation with etoposide (μM).
Cytotoxicity was measured by LDH release (C) and apoptosis by
oligonucleosomes in the cytoplasm (D). Results in (C) and (D) rep-
resent means of three independent experiments ±SD.
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sensitizing effect (Figure 7A). The experiment was repeated with a
second PAI-1 RNAi construct (#9) to ensure that this was a specific
effect. The PAI-1 RNAi construct #9 induced identical sensitizing ef-
fect as PAI-1 RNAi construct #2, suggesting that the effect of PAI-1
silencing indeed is specific (Figure 7B; #9: P < .01 and #2: P < .01).
Discussion
In the present study, we show that the Akt cell signaling pathway is
involved in PAI-1–mediated inhibition of etoposide-induced cell
death. In unstimulated wild type fibrosarcoma cells, a higher Akt
phosphorylation level was observed compared with PAI-1–deficient
fibrosarcoma cells. Pretreatment of wild type fibrosarcoma cells with
synthetic inhibitors of PI3K or Akt sensitized the cells to etoposide-
induced cell death. A similar effect was not observed in PAI-1–deficient
cells, indicating a role for the PI3K/Akt in PAI-1–expressing cells
but not in PAI-1–deficient fibrosarcoma cells. In support of this as-
sumption, reintroduction of PAI-1 into the PAI-1–deficient cells re-
sulted in an up-regulation of Akt activity and was accompanied by a
decrease in sensitivity to etoposide-induced apoptosis. Furthermore,
RNAi-mediated silencing of PAI-1 in wild type cells was accompanied
with down-regulation of phosphorylated Akt. More importantly, si-
lencing of PAI-1 by RNAi sensitized the cells to etoposide-induced cell
death, demonstrating that PAI-1 is involved in protecting the cells
against apoptosis. It is of interest to note that the levels of induction
of cell death reached by the inhibition of PI3K and Akt before etopo-
side treatment were of the same magnitude as the induction gained by
pretreatment of wild type cells with RNAi against PAI-1 before etopo-
side treatment. Thus, our data suggest that PAI-1 induces a survival
signal through the Akt cell signaling pathway leading to resistance to
etoposide-induced cell death.
Several lines of evidence suggest that PAI-1 expression can be in-
duced by the PI3K/Akt signaling pathway. Plasminogen activator in-
hibitor 1 expression can be induced by nerve growth factor in rat
pheochromocytoma cells (PC-12) and by hypoxia in hepatocellular
carcinoma cells (Hep2G), and this induction can be inhibited by
PI3K inhibitors, indicating that the PI3K/Akt signaling pathway pos-
itively regulates PAI-1 expression [33,34]. Conversely, overexpression
of a dominant-negative mutant of PI3K or Akt increases TNF-alpha–
and insulin-induced PAI-1 expression in endothelial cells [35]. Like-
wise, silencing of Akt by RNAi enhances PAI-1 expression in ovarian
cancer cells [36], suggesting that the PI3K/Akt cell signaling pathway
negatively regulates PAI-1 expression in these cell types. However,
when the PI3K/Akt cell signaling pathway was inhibited by synthetic
inhibitors of PI3K and Akt, we did not observe an induction in PAI-
1 expression in the wild type fibrosarcoma cells. Moreover, it was
studied if addition of either human stable PAI-1 or recombinant mu-
rine PAI-1 to the cells induced the phosphorylation of Akt; however,
no induction was observed. Contrary to our results, Balsara et al. [30]
have shown that treatment of the PAI-1 gene-deficient endothelial
cells with recombinant PAI-1 induced a decrease in phosphorylated
Akt levels and increased apoptosis. Furthermore, Balsara et al. found
that Akt is hyperactivated in PAI-1 gene-deficient primary endothe-
lial cells compared with the level of activation in wild type primary
Figure 5. PAI-1 mRNA and protein is down-regulated by RNAi. (A)
Pwt-I cells were treated with 50 nM PAI-1 RNAi (#2) or control
RNAi (#2Ctl) or left untreated for the indicated periods. Equal
amounts of proteins were analyzed for PAI-1 protein levels by im-
munoblot analysis. Lane 8: untreated Pwt-I cells at 95 hours.
GAPDH served as a loading control. Band densities were normal-
ized to the band density of the first lane. (B) PAI-1 mRNA levels in
Pwt-I fibrosarcoma cells after treatment with 50 nM PAI-1 RNAi
(#2) was quantified by Q-PCR. Plasminogen activator inhibitor 1
mRNA level was normalized to β-actin mRNA level. Detection of
PAI-1 down-regulation by immunoblot analysis was performed
twice with construct #2 and once with construct #9 with similar
result and Q-PCR was performed once with each construct.
Figure 6. Silencing of PAI-1 results in a reduction in phosphorylated
Akt. Equal amounts of proteins from Pko-I and Pwt-I fibrosarcoma
cells treated for 120 hours with or without 50 nM RNAi (#2) were
analyzed for protein levels of PAI-1, P-Akt (Ser473), and total-Akt by
immunoblot analysis. GAPDH served as a loading control. Band
densities of PAI-1 protein were normalized to band densities of
GAPDH. Band densities of phospho-Akt protein were normalized
to band densities of total Akt protein. The experiment was repeated
once with RNAi construct #9 with similar result.
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endothelial cells, and they suggested that this could be due to the
inactivation of PTEN. The discrepancy between our data and those
of Balsara et al. could rest in that PAI-1 induces different responses in
primary cells compared with transformed cells. In support of this as-
sumption, we have previously demonstrated that wild type and PAI-1
gene-deficient fibroblasts display equal sensitivity to etoposide-
induced apoptosis in the early passages but wild type cells gain resis-
tance to chemotherapeutic treatment during the immortalization/
transformation process in the later passages [31].
Moreover, data by Kortlever et al. [37] suggest that PAI-1 is a crit-
ical downstream target of p53 in the induction of replicative senes-
cence in primary fibroblasts and that PAI-1 knock-down leads to
activation of the PI3K-Akt-GSK-3β signaling pathway. They sug-
gested that PAI-1 regulates replicative senescence by inhibiting the
uPA-mediated increase in bioavailability of growth factors able to ac-
tivate the PI3K/Akt pathway. We have analyzed the levels of p53 in
the fibroblast/fibrosarcoma cell lines and detected high p53 levels
after passage 3 in the wild type cells and passage 6 in the PAI-1
gene-deficient cells, indicative of P53 inactivation (Lademann U, un-
published results). In contrast to the studies by Kortlever et al., our
studies were conducted with aneuploid fibrosarcoma cells in passage
30 (approximately 22 passages after crisis) [32]. It is likely to assume
that the opposing results concerning the regulation of PI3K/Akt cell
signaling pathway by PAI-1 and regulation of PAI-1 gene expression
by Akt is related to the choice of cell model and cellular settings. This
could also explain why we did not observe any effect on PAI-1 ex-
pression when inhibiting the PI3K/Akt cell signaling pathway in the
wild type cell lines.
In summary, the present study provides new insight into how PAI-
1 regulates programmed cell death in fibrosarcoma cells. The next
challenge is to uncover if and by which mechanism the survival signal
of PAI-1 is transmitted over the plasma membrane. Identification of
the exact mechanism would enable the development of specific in-
hibitors of PAI-1 survival signaling providing a new way to overcome
cancer cell resistance to chemotherapy.
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